- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03856632
Liraglutide Effect in Atrial Fibrillation (LEAF)
Novel Medical Adjunctive Therapy to Catheter Ablation For Atrial Fibrillation (AF)
The goal (or purpose) of this study is to evaluate (study) a new way to stabilize (steady) the activity between the fat deposits surrounding the heart and the left atrium.
To reduce the amount of EAT, this study will use a medication called Liraglutide. This medication is known to work on fat deposits and produce weight loss. The investigator is conducting this study to find out if Liraglutide will reduce the fat deposits surrounding the participant's heart, and stabilize (and perhaps reduce or eliminate) atrial fibrillation activity.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Florida
-
Miami, Florida, United States, 33136
- University of Miami
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male and female, age 18 or older
- Persistent AF defined as continuous AF sustained beyond 7 days (or AF with the decision to cardiovert before 7 days of enrollment or Paroxysmal AF defined as recurrent AF (≥2 episodes) that terminates spontaneously within 7 days
- BMI ≥27 kg/m2
- Patient wishes to undergo a catheter ablation procedure for the treatment of atrial fibrillation
- Receiving follow-up care at the University of Miami
Exclusion Criteria:
- Inability to sign an informed consent
- Patients with longstanding persistent atrial fibrillation of more than 3 years
- Prior ablation for atrial fibrillation
- Patients not appropriate candidates for catheter ablation such as those with AF due to acute or chronic precipitating medical conditions, for example, hypothyroidism and hyperthyroidism, significant pulmonary disease, pulmonary embolism, left atrial thrombus, class IV heart failure)
- Patients with a life expectancy <1 year
- Patients with a serious medical condition (for example, recent cancer with chemotherapy or radiation therapy within 4 weeks before entering the study) who have not recovered from adverse events due to agents administered more than 4 weeks earlier.
- Known contraindications to Liraglutide, such as the previous history of pancreatitis or medullary thyroid carcinoma
- Personal or family history of multiple endocrine neoplasias
- Known serious hypersensitivity reaction to Liraglutide
- Patients using, glitazones, sodium-glucose transporters 2 inhibitors (SGLT2i), other GLP-1 analogs, or DPP4 inhibitors
- Type 1 diabetes, defined by American Diabetes Association criteria, history of diabetic ketoacidosis, pancreas or beta-cell transplantation, or diabetes due to pancreatitis or pancreatectomy
- Poorly controlled type 2 diabetes with HbA1c > 10%
- Pregnant women
- Women who are breast-feeding or intend to become pregnant
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Risk Factor Modification (RFM)
A structured risk factor modification (RFM) program currently offered to all patients who are overweight or obese undergoing an ablation procedure for atrial fibrillation.The RFM program is already offered through our Center for Atrial Fibrillation and is managed by a nurse practitioner.
The RFM program will provide patient teaching and education on weight, fitness,blood pressure control, glucose control, cholesterol, sleep apnea, smoking, and alcohol.
|
The program involves weight management and exercise regimen (30 minutes for 2 to 4 times a week), hyperlipidemia management (lifestyle measure changes and initiation of statins and fibrates if necessary), management of obstructive sleep apnea (initiation of Continuous Positive Airway Pressure (CPAP) if necessary), management of hypertension (reduction of salt intake, initiation of Angiotensin Converting Enzyme Inhibitor (ACEI) or Angiotensin II Receptor blockers (ARB) medications if necessary), diabetes management (lifestyle measure changes, endocrine review and initiation of metformin if necessary) and smoking cessation and alcohol abstinence or reduction.
This program will be performed at start of study participation all throughout the follow up period.
The choice of antiarrhythmic drug will be at the discretion of the managing physician, but will generally include either a class IC or class III antiarrhythmic drug.
If necessary, and clinically indicated, amiodarone may be used.
Therapy will be initiated at the start of study participation and will be discontinued 6-12 weeks after the ablation, as deemed clinically appropriate by the managing electrophysiologist.
The procedure will be performed according to usual clinical practice.
The primary approach will be antral pulmonary vein isolation (PVI), preferably performed by cryoballoon ablation, though radiofrequency may be used as deemed necessary by the operator for clinical reasons.
This will be performed after 3 months of RFM or RFM + Liraglutide program.
|
Experimental: RFM plus Liraglutide
In addition to RFM, Liraglutide will be administered.
Liraglutide is an FDA approved medication used as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management of obese adults with weight-related comorbid conditions.
|
The program involves weight management and exercise regimen (30 minutes for 2 to 4 times a week), hyperlipidemia management (lifestyle measure changes and initiation of statins and fibrates if necessary), management of obstructive sleep apnea (initiation of Continuous Positive Airway Pressure (CPAP) if necessary), management of hypertension (reduction of salt intake, initiation of Angiotensin Converting Enzyme Inhibitor (ACEI) or Angiotensin II Receptor blockers (ARB) medications if necessary), diabetes management (lifestyle measure changes, endocrine review and initiation of metformin if necessary) and smoking cessation and alcohol abstinence or reduction.
This program will be performed at start of study participation all throughout the follow up period.
The choice of antiarrhythmic drug will be at the discretion of the managing physician, but will generally include either a class IC or class III antiarrhythmic drug.
If necessary, and clinically indicated, amiodarone may be used.
Therapy will be initiated at the start of study participation and will be discontinued 6-12 weeks after the ablation, as deemed clinically appropriate by the managing electrophysiologist.
The procedure will be performed according to usual clinical practice.
The primary approach will be antral pulmonary vein isolation (PVI), preferably performed by cryoballoon ablation, though radiofrequency may be used as deemed necessary by the operator for clinical reasons.
This will be performed after 3 months of RFM or RFM + Liraglutide program.
Liraglutide will be administered with a starting dose of 0.6 mg once daily and subsequent increments to 1.2 mg once daily (after at least one week) and to 1.8 mg once daily (after at least a week on 1.2 mg).
This will be taken for 3 consecutive months in conjunction with RFM program prior to catheter ablation.
Treatment will resume post ablation and will be continue for 6 months.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in size of Left Atrial Epicardial Adipose Tissue (LAEAT)
Time Frame: Baseline, 3 months (prior to ablation)
|
As assessed via multi detector cardiac computer tomography (MD-CT)
|
Baseline, 3 months (prior to ablation)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in size of Epicardial Adipose Tissue (EAT) thickness
Time Frame: Baseline, 3 months (prior to ablation), 1 year post-ablation
|
As assessed via echocardiography
|
Baseline, 3 months (prior to ablation), 1 year post-ablation
|
Change in atrial function
Time Frame: Baseline, 1 year post ablation
|
As assessed via echocardiography
|
Baseline, 1 year post ablation
|
Change in atrial size
Time Frame: Baseline, 1 year post ablation
|
As assessed via echocardiography
|
Baseline, 1 year post ablation
|
Change in C-Reactive Protein (CRP) value
Time Frame: Baseline, 1 year post ablation
|
Serial changes in biomarkers of inflammation
|
Baseline, 1 year post ablation
|
Change in Interleukin-6 (IL-6)
Time Frame: Baseline, 1 year post ablation
|
Serial changes in biomarkers of inflammation
|
Baseline, 1 year post ablation
|
Correlation of CRP expression in blood from left atrium to peripheral plasma
Time Frame: During the catheter ablation procedure
|
At the same time point, blood will be collected directly from left atrium and peripheral vessel during the ablation procedure and compared
|
During the catheter ablation procedure
|
Correlation of IL-6 expression in blood from left atrium to peripheral plasma
Time Frame: During the catheter ablation procedure
|
At the same time point blood, will be collected directly from left atrium and the peripheral vessel during the ablation procedure and compared
|
During the catheter ablation procedure
|
Correlation of plasminogen activator inhibitor (PAI-1), matrix metalloproteinase-2 (MMP2), Tissue inhibitor of metalloproteinase 2 (TIMP-2)
Time Frame: During the catheter ablation procedure
|
At the same time point, blood will be collected directly from left atrium and the peripheral vessel during the ablation procedure and compared
|
During the catheter ablation procedure
|
Correlation of atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP)
Time Frame: During the catheter ablation procedure
|
At the same time point, blood will be collected directly from left atrium and the peripheral vessel during the ablation procedure and compared
|
During the catheter ablation procedure
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Jeffrey Goldberger, MD, University of Miami
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Heart Diseases
- Cardiovascular Diseases
- Arrhythmias, Cardiac
- Atrial Fibrillation
- Hypoglycemic Agents
- Physiological Effects of Drugs
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Incretins
- Glucagon-Like Peptide-1 Receptor Agonists
- Liraglutide
- Anti-Arrhythmia Agents
Other Study ID Numbers
- 20181182
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Atrial Fibrillation
-
Ablacon, Inc.CompletedArrhythmias, Cardiac | Atrial Fibrillation, Persistent | Persistent Atrial Fibrillation | Longstanding Persistent Atrial FibrillationGermany
-
Ablacon, Inc.RecruitingAtrial Fibrillation | Arrhythmias, Cardiac | Arrhythmia | Atrial Flutter | Atrial Fibrillation, Persistent | Atrial Tachycardia | Atrial Arrhythmia | Atrial Fibrillation Paroxysmal | Atrial Fibrillation, Paroxysmal or PersistentUnited States, Belgium, Netherlands, Czechia
-
AtriCure, Inc.Active, not recruitingPersistent Atrial Fibrillation | Atrial Fibrillation (AF) | Longstanding Persistent Atrial FibrillationUnited States
-
Barts & The London NHS TrustAtriCure, Inc.Not yet recruitingAtrial Fibrillation, Persistent | Persistent Atrial Fibrillation | Atrial Arrhythmia | Atrium; FibrillationUnited Kingdom
-
Maastricht University Medical CenterRWTH Aachen UniversityUnknownAtrial Fibrillation (Paroxysmal) | Atrial Fibrillation Recurrent | Atrial Fibrillation Common Gene VariantsNetherlands
-
Vivek ReddyEnrolling by invitationAtrial Fibrillation and Flutter | Atrial Flutter Typical | Atrial Fibrillation, Paroxysmal or PersistentUnited States
-
Fundació Institut de Recerca de l'Hospital de la...RecruitingAtrial Arrhythmia | Atrial Fibrillation and Flutter | Atrial Fibrillation RecurrentSpain
-
Adagio MedicalRecruitingAtrial Fibrillation | Atrial Flutter | Paroxysmal Atrial Fibrillation | Persistent Atrial FibrillationNetherlands, Germany, Belgium
-
Beijing Anzhen HospitalJohnson & Johnson; Heart Health Research CenterNot yet recruitingParoxysmal Atrial Fibrillation | Persistent Atrial Fibrillation
-
Maastricht UniversityRadboud University Medical Center; Maastricht University Medical CenterRecruitingAtrial Fibrillation | Atrial Fibrillation, Persistent | Atrial Fibrillation ParoxysmalNetherlands
Clinical Trials on RFM
-
University Hospital of North NorwayCompleted
-
Manuel Sanchez LunaCompleted
-
US Department of Veterans AffairsThe Alfred E. Mann Foundation for Scientific ResearchTerminatedStrokeUnited States
-
University of AlbertaCompleted
-
The Alfred E. Mann Foundation for Scientific ResearchVA Office of Research and DevelopmentCompletedHemiparesisUnited States
-
International Evangelical HospitalCompleted
-
The Alfred E. Mann Foundation for Scientific ResearchTerminatedTraumatic Brain InjuryUnited States